Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MDVN's 30-Y Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MDVN Guru Trades in Q4 2015

Pioneer Investments 149,693 sh (New)
Paul Tudor Jones 127,060 sh (+882.37%)
Steven Cohen 2,002,700 sh (+22.02%)
Ken Fisher 6,615 sh (+5.00%)
Jim Simons Sold Out
» More
Q1 2016

MDVN Guru Trades in Q1 2016

Columbia Wanger 1,780,000 sh (New)
Jim Simons 207,600 sh (New)
Joel Greenblatt 327,094 sh (New)
Andreas Halvorsen 707,319 sh (New)
Paul Tudor Jones 661,185 sh (+420.37%)
Pioneer Investments 400,496 sh (+167.54%)
Ken Fisher 6,631 sh (+0.24%)
Steven Cohen 291,100 sh (-85.46%)
» More
Q2 2016

MDVN Guru Trades in Q2 2016

George Soros 12,800 sh (New)
Mario Gabelli 20,200 sh (New)
Lee Ainslie 52,620 sh (New)
Eric Mindich 3,082,209 sh (New)
Eaton Vance Worldwide Health Sciences Fund 292,900 sh (New)
Jim Simons 852,100 sh (+310.45%)
Steven Cohen 433,200 sh (+48.81%)
Joel Greenblatt 348,619 sh (+6.58%)
Andreas Halvorsen Sold Out
Ken Fisher 6,591 sh (-0.60%)
Pioneer Investments 253,445 sh (-36.72%)
Columbia Wanger 426,668 sh (-76.03%)
Paul Tudor Jones 3,500 sh (-99.47%)
» More
Q3 2016

MDVN Guru Trades in Q3 2016

Columbia Wanger Sold Out
Lee Ainslie Sold Out
George Soros Sold Out
Ken Fisher Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Eric Mindich Sold Out
Pioneer Investments Sold Out
Mario Gabelli Sold Out
Joel Greenblatt Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2016-09-30 Sold Out $60.12 - $81.44 $ 81.4415%0
Mario Gabelli 2016-09-30 Sold Out 0.01%$60.12 - $81.44 $ 81.4415%0
George Soros 2016-09-30 Sold Out 0.02%$60.12 - $81.44 $ 81.4415%0
Joel Greenblatt 2016-09-30 Sold Out 0.25%$60.12 - $81.44 $ 81.4415%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Traded in other countries:WMD.Germany,
Headquarter Location:USA
Medivation Inc is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer's disease and Huntington disease.

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Top Ranked Articles about Medivation Inc

Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Steven Cohen Increases Position in Dynavax Company is one of many biopharmaceutical holdings
Steven Cohen (Trades, Portfolio) of Point72 Asset Management increased his position in Dynavax Technologies Corp. (NASDAQ:DVAX) by 375.26% on Sept. 29. Read more...



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $1,027.08
EPS (TTM) $ -1.10
Short Percentage of Float2.49%
52-Week Range $26.41 - 81.48
Shares Outstanding (Mil)165.93

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 917 1,208 1,429 1,676
EPS ($) 1.47 2.28 3.10 3.92
EPS without NRI ($) 1.47 2.28 3.10 3.92
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)
» More Articles for NAS:MDVN


Articles On GuruFocus.com
How a 15% Decline Is a Gift to Income Investors Nov 21 2016 
Pfizer Refuses to Go the Spinoff Route Oct 17 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
Sanofi Sues Merck Over Patent Infringement Sep 20 2016 
Pfizer: Hospira Is Future; Xtandi Is Today’s Meal Sep 19 2016 
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Pfizer Acquires Medivation Aug 22 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 

More From Other Websites
Medivation Founder Takes Helm at Axovant, Shares Spike Apr 10 2017
How I'd Play Biotech Buyout Rumors Mar 26 2017
Clovis, Tesaro Soar on Astrazeneca Phase Three News Feb 17 2017
Pfizer quarterly revenue slips 3 percent Jan 31 2017
The Best Biopharma CEOs of 2016 Are... Dec 19 2016
My Biggest Investing Regret of 2016 Dec 12 2016
Is ONEOK, Inc. (OKE) Going to Burn You? Dec 05 2016
How a 15% Decline Is a Gift to Income Investors Nov 21 2016
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare... Nov 18 2016
After FDA Approval, Merck Posts Better-Than-Expected Earnings Oct 25 2016
Tesaro Inc. Is Flying High Today (and Could Go Higher From Here) Oct 11 2016
Gilead's Patience Is Wearing Investors' Patience Thin Oct 10 2016
Tesaro Bolts On Ovarian Cancer Win Vs. AstraZeneca, AbbVie Oct 10 2016
New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly... Oct 09 2016
Biotech Mergers Run the Show: 5 Small-Cap Stocks for Q4 Oct 04 2016
Key FDA Decisions and Trial Results Expected in October Oct 04 2016
What’s the Outlook for Pfizer? Oct 03 2016
Vigorous M&A Activity Signals Economic Health Oct 03 2016
A Look at the Pfizer-Medivation Deal Sep 29 2016
Pfizer Completes Acquisition of Medivation Sep 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat